Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 5Colorectal Neoplasms 3Lung Neoplasms 2Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lung Diseases 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma, Intraductal, Noninfiltrating 1Cachexia 1Breast Carcinoma In Situ 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 8Pemetrexed 3Paclitaxel 3durvalumab 2atezolizumab 2Nivolumab 2Ipilimumab 2Cisplatin 2Bevacizumab 2zipalertinib 1toripalimab 1sotorasib 1sitravatinib 1sintilimab 1pembrolizumab 1necitumumab 1demcizumab 1ceralasertib 1cemiplimab 1camrelizumab 1apatinib 1aflibercept 1Toll-Like Receptor 1 1Radiotherapy 1Omacor 1Gemcitabine 1Etoposide 1Erlotinib Hydrochloride 1Diarylheptanoids 1Diagnostic Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Diseases × Omacor × Clear all
NCT03598309 2026-02-27

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
19 enrolled
Thoracic

Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡